🇺🇸 FDA
Patent

US 9346759

Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor

granted A61KA61K31/4704A61K45/06

Quick answer

US patent 9346759 (Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor) held by Almirall, S.A. expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Almirall, S.A.
Grant date
Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/4704, A61K45/06, A61P, A61P11/00